No Data
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Rodman & Renshaw Initiates Heron Therapeutics(HRTX.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Heron Therapeutics(HRTX.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Northland Securities analyst Carl Byrnes maintains $Heron Therapeutics(HRTX.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 3
TrytosaveabitOP : Before EOY ((((. Heron Anticipates FDA Action on Zynrelef Within 4-6 Months ))))